Endocrine Abstracts

Introduction: According to the FDA, narrow therapeutic index (NTI) medications are those in which small differences in dosage orblood concentration can lead to serious therapeutic failures and/or adverse reactions that can endanger the patient’s life or result inpersistent or significant disability or incapacity. A literature not have studies about used this medication use in endocrinology pediatric population. OBJECTIVE: Establish the prescription profile of narrow therapeutic index medications used in pediatric endocrinology in patients included General Health System of Colombia between January 1st and December 31st, 2021.

Materials & Methods: Descriptive cross-sectional study. Convenience sampling collect data from the dispensing database of a pharmaceutical manager in Colombia for patients under 18 years old who received narrow therapeutic index medications included in the DrugBankdatabase between January 1st and December 31st, 2021. This research was classified as a no-risk investigation approval from CEISH with the code 0405-2022. Regarding the analysis plan, univariate analysis was performed for qualitative variables, which were described using measures of absolute and relative frequency.

Results: For the period between January 1st, 2021, and December 31st, 2021, medications were dispensed to 777,924 pediatric patients of 24,053 received narrow therapeutic index medications, prevalence of 3.09%. Regarding the ATC category for endocrinology, 13.86% (n= 3480) used thyroid therapy, 0.17% (n= 43) other gynecologicals, 0.04% (n=9) endocrine therapy and 0.02% (n=4) lipid modifying agents. Regarding the molecules, out of the 254 medications registered in DrugBank, 56 medications were dispensed to the pediatric population, of which 5 are used in endocrinology. The most commonly dispensed medication was Levothyroxine, accounting for 14.5% (n=3480) of the patients, followed by 0.2% (n=43) Cabergoline, 0,03% (n=9) Tamoxifen, 0.02% (n=4) Lomitapide and 0.01% (n=1) Bicalutamide

Conclusion: Out of 254 narrow therapeutic index medications registered worldwide, 5 are used in endocrinology and were dispensed to the pediatric population.